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Abstract 
Background: To investigate the long-term efficacy and safety of empagliflozin monotherapy compared with  
placebo and sitagliptin in drug-naïve patients with type 2 diabetes mellitus.
Methods: Of 899 patients randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, placebo, or sitagliptin 
100 mg once daily for 24 weeks, 615 continued in a double-blind extension trial for ≥52 weeks. Exploratory endpoints 
included changes from baseline in HbA1c, weight and blood pressure at week 76.
Results: Compared with placebo, adjusted mean changes from baseline in HbA1c at week 76 were −0.78 % (95 % CI 
−0.94, −0.63; p < 0.001) and −0.89 % (95 % CI −1.04, −0.73; p < 0.001) for empagliflozin 10 mg and 25 mg,  
respectively. Compared with placebo, adjusted mean changes from baseline in weight at week 76 were −1.8 kg (95 % 
CI −2.4, −1.3; p < 0.001) and −2.0 kg (95 % CI −2.6, −1.5; p < 0.001) for empagliflozin 10 mg and 25 mg, respectively. 
Empagliflozin led to reductions in systolic blood pressure (SBP) compared with placebo in the primary analysis but 
not in sensitivity analyses. Compared with sitagliptin, empagliflozin 25 mg reduced HbA1c and both empagliflozin 
doses reduced weight and SBP. Adverse events (AEs) were reported in 76.8, 78.0, 76.4 and 72.2 % of patients on  
empagliflozin 10 mg, empagliflozin 25 mg, placebo and sitagliptin, respectively. Confirmed hypoglycaemic AEs  
(glucose ≤3.9 mmol/l and/or requiring assistance) were reported in two patients (0.9 %) per treatment group.
Conclusions: Empagliflozin monotherapy for ≥76 weeks was well tolerated and led to sustained reductions in 
HbA1c and weight compared with placebo.
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Keywords: Type 2 diabetes, Empagliflozin, SGLT2 inhibitor, Safety, Blood pressure
© 2015 Roden et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Inhibition of the sodium glucose cotransporter 2 
(SGLT2), located in the proximal tubule of the kidney, 
leads to increased urinary glucose excretion (UGE) and 
a reduction in plasma glucose levels in patients with type 
2 diabetes mellitus (T2DM) [1–4]. This mechanism of 
action is associated with a low risk of hypoglycaemia, 
with additional benefits of weight loss and reductions in 
blood pressure [1, 5, 6].
Empagliflozin is a potent and selective SGLT2 inhibitor 
[7], which, when given as monotherapy or as add-on 
therapy for T2DM, has consistently reduced HbA1c, 
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weight and systolic blood pressure (SBP) compared with 
placebo [8–16]. As well as reducing fasting plasma glu-
cose (FPG), empagliflozin reduces post-prandial glucose 
in patients with T2DM [17].
In a Phase III, parallel-group, randomized, double-blind 
trial in drug-naïve patients with T2DM (EMPA-REG 
MONO™), empagliflozin 10 mg and 25 mg and the dipep-
tidyl peptidase-4 (DPP-4) inhibitor sitagliptin 100  mg 
given as monotherapy for 24  weeks were well tolerated 
and improved glycaemic control. Adjusted mean dif-
ferences versus placebo in change from baseline in hae-
moglobin A1c (HbA1c) at week 24 were −0.74  % for 
empagliflozin 10 mg and −0.85 % for empagliflozin 25 mg, 
with no significant difference in change from baseline in 
HbA1c between empagliflozin and sitagliptin. Treatment 
with empagliflozin also significantly reduced body weight 
and SBP compared with placebo and sitagliptin [9].
This 52-week extension to the above study, EMPA-REG 
EXTEND™ MONO, evaluated the long-term safety, tol-
erability and efficacy of empagliflozin 10 mg and 25 mg 




In the initial 24-week study, drug-naïve patients with 
T2DM (no oral or injectable anti-diabetes therapy for 
≥12  weeks prior to randomization) with insufficient 
glycaemic control despite a diet and exercise regimen 
(HbA1c ≥7 to ≤10  %, or HbA1c ≥7 to ≤9  % in Ger-
many) and body mass index ≤45  kg/m2 were enrolled. 
Key exclusion criteria included uncontrolled hypergly-
caemia (glucose concentration >13.3  mmol/l following 
an overnight fast, confirmed by a second measurement), 
an estimated glomerular filtration rate (eGFR) [Modi-
fication of Diet in Renal Disease (MDRD) formula] 
<50 ml/min/1.73 m2, indication of liver disease, and con-
traindications to sitagliptin according to the local label [9].
In the initial study, patients were randomized (1:1:1:1) 
to receive empagliflozin 10  mg, empagliflozin 25  mg, 
sitagliptin 100  mg, or placebo once daily for 24  weeks. 
Patients who completed 24  weeks’ treatment, who still 
did not contravene the exclusion criteria for the initial 
study, and who did not contravene additional exclusion 
criteria for the extension study, e.g., eGFR <30 ml/min at 
the last visit of the initial trial, could decide to continue 
their double-blind treatment for ≥52 weeks (i.e., a total 
treatment duration of ≥76 weeks). Patients remained on 
the treatments they received in the initial study, but were 
required to re-confirm their consent before starting the 
extension trial. The initial trial and the extension trial 
were registered with clinicaltrials.gov (NCT01177813 
and NCT01289990, respectively) and were carried out in 
compliance with the protocols and the principles of the 
Declaration of Helsinki, and in accordance with the Inter-
national Conference on Harmonization Harmonized Tri-
partite Guideline for Good Clinical Practice. The studies 
were approved by Institutional Review Boards, Inde-
pendent Ethics Committees and Competent Authorities 
according to national and international regulations.
During the extension trial, patients continued to 
receive diet and exercise counselling based on local rec-
ommendations. Patients who received rescue medication 
during the initial 24-week study and were still receiving it 
at the start of the extension study were to continue their 
rescue medication throughout the extension study. Res-
cue medication could be initiated during the extension 
trial if a patient had a confirmed plasma glucose level 
>10 mmol/l after an overnight fast or HbA1c >8 %. The 
choice and dose of rescue medication were at the discre-
tion of the investigator, except that DPP-4 inhibitors and 
glucagon-like peptide-1 analogues were not permitted. In 
cases of hypoglycaemia, dose reduction or discontinua-
tion of rescue medication was to be initiated. If hyper- or 
hypoglycaemia could not be controlled, the patient was 
to be discontinued from the trial.
Endpoints and assessments
The primary efficacy endpoint of change from baseline 
in HbA1c at week 24 was analyzed in the initial trial [9]. 
No primary endpoint was defined for the extension study. 
Exploratory efficacy endpoints in the extension trial were 
change from baseline in HbA1c, FPG, body weight, SBP 
and diastolic blood pressure (DBP) at week 52 and week 
76. Other exploratory endpoints were the percentage of 
patients who were treated in the extension trial and had 
HbA1c ≥7 % at baseline who reached HbA1c <7 % at week 
76 and the use of rescue therapy over 76 weeks. Baseline 
was defined as the last observed measurement before the 
first administration of study drug in the initial trial.
Safety was assessed through the reporting of adverse 
events [AEs; coded using the Medical Dictionary for 
Drug Regulatory Activities (MedDRA), version 16.0]. 
AEs of special interest included confirmed hypoglycae-
mic events (plasma glucose ≤3.9 mmol/l and/or requir-
ing assistance) and AEs consistent with urinary tract 
infection (UTI), genital infection and volume depletion, 
which were identified using prospectively defined search 
categories based on 77, 89 and 8 MedDRA preferred 
terms, respectively. Changes from baseline in clinical lab-
oratory values at week 76 were also assessed.
Statistical analyses
No formal sample size calculation was performed for the 
extension trial; the extension trial was open to all patients 
who were eligible to participate.
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Changes from baseline in HbA1c, FPG, weight, SBP and 
DBP at week 52 and 76 were analyzed using an analysis of 
covariance (ANCOVA) model in the full analysis set (FAS: 
patients who received ≥1 dose of study drug and had a 
baseline HbA1c measurement in the initial study) with 
baseline HbA1c and the baseline value of the endpoint in 
question as linear covariates, and baseline eGFR (MDRD), 
region and treatment as fixed effects. Data following ini-
tiation of rescue therapy were set to missing and missing 
data were imputed using the last observation carried for-
ward (LOCF) approach. The percentage of patients reach-
ing HbA1c <7 % at week 76 was assessed in patients from 
the FAS who were treated in the extension trial using a 
logistic regression model that included treatment, base-
line eGFR, region and baseline HbA1c, with non-com-
pleters considered failures (patients who did not enter the 
extension trial were not considered non-completers).
Changes over time in HbA1c, FPG, weight, SBP and 
DBP were analyzed by means of sensitivity analyses using 
a restricted maximum likelihood-based mixed model 
repeated measures (MMRM) approach with baseline 
HbA1c and the baseline value of the endpoint in question 
as linear covariates, and baseline eGFR, region, treat-
ment, visit, and visit by treatment interaction as fixed 
effects, based on observed cases (OC) in the FAS and 
in FAS-completers. The FAS-completers set comprised 
patients from the FAS who completed 76  ±  1  weeks’ 
treatment and had an HbA1c measurement at the week 
76 visit. The use of rescue therapy was assessed in the 
FAS using logistic regression, including treatment as a 
factor and baseline HbA1c as a covariate.
Safety was assessed in the treated set (patients treated 
with ≥1 dose of study drug in the initial study) and analy-
ses were descriptive, except for changes from baseline in 
lipid parameters, which were assessed using ANCOVA 
with the baseline value and baseline HbA1c as linear 




The FAS comprised 899 patients. The demographic and 
baseline characteristics of the FAS were balanced across 
treatment groups and are summarized in Table  1. Of 
these 899 patients, 615 (68.4 %) continued in the exten-
sion study (Fig.  1). The baseline characteristics of the 
patients who continued in the extension trial were com-
parable with the baseline characteristics of the overall 
patient population treated in the initial 24-week study.
Efficacy
Reductions in HbA1c at week 76 were greater with both 
doses of empagliflozin compared with placebo. Differ-
ences of adjusted means versus placebo were −0.78  % 
[95  % confidence interval (CI) −0.94, −0.63] with 
empagliflozin 10  mg and −0.89  % (−1.04, −0.73) with 
Table 1 Baseline characteristics














Male 123 (53.9) 142 (63.4) 145 (64.7) 141 (63.2) 551 (61.3)
Age (years) 54.9 ± 10.9 56.2 ± 11.6 53.8 ± 11.6 55.1 ± 9.9 55.0 ± 11.0
Race
 Asian 146 (64.0) 143 (63.8) 144 (64.3) 143 (64.1) 576 (64.1)
 White 76 (33.3) 77 (34.4) 73 (32.6) 76 (34.1) 302 (33.6)
 Black/African-American 6 (2.6) 3 (1.3) 7 (3.1) 3 (1.3) 19 (2.1)
 Other 0 1 (0.4) 0 1 (0.4) 2 (0.2)
Time since diagnosis of T2DM (years)
 ≤1 72 (31.6) 87 (38.8) 91 (40.6) 93 (41.7) 343 (38.2)
 >1–5 104 (45.6) 92 (41.1) 83 (37.1) 86 (38.6) 365 (40.6)
 >5–10 33 (14.5) 29 (12.9) 37 (16.5) 32 (14.3) 131 (14.6)
 >10 19 (8.3) 16 (7.1) 13 (5.8) 12 (5.4) 60 (6.7)
Body weight (kg) 78.2 ± 19.9 78.4 ± 18.7 77.8 ± 18.0 79.3 ± 20.4 78.4 ± 19.2
Body mass index (kg/m2) 28.7 ± 6.2 28.3 ± 5.5 28.2 ± 5.5 28.2 ± 5.2 28.4 ± 5.6
HbA1c (%) 7.91 ± 0.78 7.87 ± 0.88 7.86 ± 0.85 7.85 ± 0.79 7.88 ± 0.82
FPG (mmol/l) 8.6 ± 2.0 8.5 ± 1.8 8.5 ± 1.9 8.2 ± 1.6 8.4 ± 1.8
SBP (mmHg) 130.4 ± 16.3 133.0 ± 16.6 129.9 ± 17.5 132.5 ± 15.8 131.4 ± 16.6
DBP (mmHg) 78.9 ± 9.6 79.2 ± 9.6 78.3 ± 9.4 80.1 ± 10.0 79.1 ± 9.6
eGFR (ml/min/1.73 m2) (MDRD) 86.8 ± 17.9 87.7 ± 19.2 87.6 ± 18.3 87.6 ± 17.3 87.4 ± 18.2
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empagliflozin 25 mg; p < 0.001 for both doses (Table 2). 
Compared with sitagliptin, adjusted mean changes 
from baseline in HbA1c at week 76 were greater for 
empagliflozin 25  mg (differences of adjusted means 
−0.22 %, 95 % CI −0.38, −0.07, p = 0.005), but not for 
empagliflozin 10  mg (Table  2). Adjusted mean HbA1c 
values over 76 weeks are presented in Fig. 2a. The results 
of sensitivity analyses based on MMRM OC analyses in 
the FAS and FAS-completers were consistent with those 
from the ANCOVA LOCF analysis in the FAS (Addi-
tional file  1). The proportion of patients treated in the 
extension trial who had HbA1c ≥7  % at baseline who 
reached HbA1c <7  % at week 76 was greater with both 
empagliflozin doses compared with placebo and with 
empagliflozin 10 mg compared with sitagliptin (Fig. 2b).
At week 76, reductions in FPG were greater for both 
empagliflozin doses compared with placebo or sitag-
liptin (Table  2). Differences of adjusted means versus 
placebo were −1.8  mmol/l (95  % CI −2.1, −1.4) with 
empagliflozin 10  mg and −1.9  mmol/l (95  % CI −2.3, 
−1.6) with empagliflozin 25 mg; p < 0.001 for both doses. 
Differences of adjusted means versus sitagliptin were 
−0.9  mmol/l (95  % CI −1.2, −0.5) with empagliflozin 
10 mg and −1.0 mmol/l (95 % CI −1.4, −0.7) with empa-
gliflozin 25 mg; p < 0.001 for both doses. Figure 2c shows 
the adjusted mean changes from baseline in FPG over 
the 76-week treatment period. The results of sensitivity 
analyses based on MMRM OC in the FAS and FAS-com-
pleters were consistent with findings from the ANCOVA 
LOCF analysis in the FAS (Additional file 1).
The proportions of patients who received rescue medi-
cation up to week 76 were 32.5  % for placebo versus 
12.1  % for empagliflozin 10  mg [odds ratio (OR) 0.25, 
95  % CI 0.15, 0.41, p  <  0.001], 5.8  % for empagliflozin 
25 mg (OR 0.11, 95 % CI 0.05, 0.20, p < 0.001) and 15.7 % 
for sitagliptin (OR 0.37, 95  % CI 0.23, 0.60, p  <  0.001). 
When compared with sitagliptin, ORs were 0.67 (95 % CI 
0.38, 1.18, p =  0.163) for empagliflozin 10  mg and 0.29 
(95 % CI 0.14, 0.57, p < 0.001) for empagliflozin 25 mg.
At week 76, empagliflozin 10 mg and 25 mg resulted in 
a decrease in weight compared with placebo or sitagliptin 
(Table  2). Differences of adjusted means versus placebo 
were −1.8  kg (95  % CI −2.4, −1.3) with empagliflozin 
10 mg and −2.0 kg (95 % CI −2.6, −1.5) with empagli-
flozin 25  mg; p  <  0.001 for both doses. Differences of 
adjusted means versus sitagliptin were −2.3 kg (95 % CI 
−2.9, −1.8) with empagliflozin 10 mg and −2.6 kg (95 % 
CI −3.1, −2.0) with empagliflozin 25  mg; p  <  0.001 for 
both doses. Adjusted mean changes from baseline in 
weight over the 76-week trial period are shown in Fig. 3. 
The results of sensitivity analyses based on MMRM OC 
(FAS and FAS-completers) were consistent with those 
from the ANCOVA LOCF analysis in the FAS (Addi-
tional Table 1).
Significant reductions in SBP were noted for empa-
gliflozin 10  mg and 25  mg compared with placebo and 
sitagliptin at week 76 (Table  2). Differences of adjusted 
means versus placebo were −3.4  mmHg (95  % CI 
−5.5, −1.2) with empagliflozin 10  mg (p  =  0.003) and 
−3.4  mmHg (95  % CI −5.6, −1.2) with empagliflozin 
Fig. 1 Study flow
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25 mg (p = 0.002). Differences of adjusted means versus 
sitagliptin were −3.7  mmHg (95  % CI −5.9, −1.6) with 
empagliflozin 10  mg and −3.8  mmHg (95  % CI −6.0, 
−1.6) with empagliflozin 25  mg; p  =  0.001 for both 
doses. Adjusted mean changes from baseline in SBP up 
to week 76 are presented in Additional file 2. Sensitivity 
analyses based on MMRM OC in the FAS and FAS-com-
pleters showed no difference in adjusted mean change 
from baseline in SBP between empagliflozin 10  mg or 
empagliflozin 25 mg and placebo at week 76, but signifi-
cant differences between both doses of empagliflozin and 
sitagliptin (Additional file 1).
At week 76, the reductions in DBP with empagliflozin 
10  mg and 25  mg were not significantly different com-
pared with placebo, but a significant decrease was noted 
for both doses when compared with sitagliptin (Table 2). 
Adjusted mean changes in DBP up to week 76 are pre-
sented in Additional file 3. Sensitivity analyses based on 
MMRM OC in the FAS and FAS-completers showed no 
difference in adjusted mean change from baseline in DBP 
for either empagliflozin dose compared with placebo or 
for empagliflozin 25  mg compared with sitagliptin, but 
showed a significant difference between empagliflozin 
10 mg and sitagliptin at week 76 (Additional file 1).
No clinically meaningful changes in pulse rate were 
observed. Mean (standard deviation) changes from base-
line in pulse rate were −0.2 (9.9), −0.5 (9.0), −1.0 (8.4) 
and −0.3 (10.1) beats per minute with placebo, empa-
gliflozin 10  mg, empagliflozin 25  mg and sitagliptin, 
respectively.
The results of exploratory efficacy analyses at week 52 
were consistent with those observed at week 76, except 
Table 2 Summary of efficacy results at week 76












HbA1c at week 76 (%) 8.01 ± 0.06 7.22 ± 0.06 7.12 ± 0.06 7.34 ± 0.06
 Change from baseline 0.13 ± 0.06 −0.65 ± 0.06 −0.76 ± 0.06 −0.53 ± 0.06
 Difference vs. placebo (95 % CI) −0.78 (−0.94, −0.63) −0.89 (−1.04, −0.73) −0.66 (−0.82, −0.51)
 p value <0.001 <0.001 <0.001
 Difference vs. sitagliptin (95 % CI) −0.12 (−0.28, 0.04) −0.22 (−0.38, −0.07)
 p value 0.131 0.005
FPG at week 76 (mmol/l) 9.2 ± 0.1 7.5 ± 0.1 7.3 ± 0.1 8.3 ± 0.1
 Change from baseline 0.8 ± 0.1 −1.0 ± 0.1 −1.1 ± 0.1 −0.1 ± 0.1
 Difference vs. placebo (95 % CI) −1.8 (−2.1, −1.4) −1.9 (−2.3, −1.6) −0.9 (−1.2, −0.6)
 p value <0.001 <0.001 <0.001
 Difference vs. sitagliptin (95 % CI) −0.9 (−1.2, −0.5) −1.0 (−1.4, −0.7)
 p value <0.001 <0.001
Body weight at week 76 (kg) 78.0 ± 0.2 76.2 ± 0.2 76.0 ± 0.2 78.5 ± 0.2
 Change from baseline −0.4 ± 0.2 −2.2 ± 0.2 −2.5 ± 0.2 0.1 ± 0.2
 Difference vs. placebo (95 % CI) −1.8 (−2.4, −1.3) −2.0 (−2.6, −1.5) 0.5 (0.0, 1.1)
 p value <0.001 <0.001 0.055
 Difference vs. sitagliptin (95 % CI) −2.3 (−2.9, −1.8) −2.6 (−3.1, −2.0)
 p value <0.001 <0.001
SBP at week 76 (mmHg) 130.7 ± 0.8 127.3 ± 0.8 127.3 ± 0.8 131.1 ± 0.8
 Change from baseline −0.7 ± 0.8 −4.1 ± 0.8 −4.2 ± 0.8 −0.3 ± 0.8
 Difference vs. placebo (95 % CI) −3.4 (−5.5, −1.2) −3.4 (−5.6, −1.2) 0.4 (−1.8, 2.6)
 p value 0.003 0.002 0.724
 Difference vs. sitagliptin (95 % CI) −3.7 (−5.9, −1.6) −3.8 (−6.0, −1.6)
 p value 0.001 0.001
DBP at week 76 (mmHg) 78.5 ± 0.5 77.5 ± 0.5 77.5 ± 0.5 79.0 ± 0.5
 Change from baseline −0.6 ± 0.5 −1.6 ± 0.5 −1.6 ± 0.5 −0.1 ± 0.5
 Difference vs. placebo (95 % CI) −1.0 (−2.3, 0.4) −1.0 (−2.4, 0.3) 0.5 (−0.8, 1.9)
 p value 0.157 0.132 0.433
 Difference vs. sitagliptin (95 % CI) −1.5 (−2.8, −0.2) −1.6 (−2.9, −0.2)
 p value 0.029 0.023
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that DBP was significantly reduced with empagliflo-
zin 25  mg compared with placebo but not significantly 
reduced with empagliflozin 10 mg compared with sitag-
liptin (Additional file 4).
Safety and tolerability
Median exposure was 17.3, 20.2, 20.2 and 18.1  months 
in the placebo, empagliflozin 10  mg, empagliflozin 
25  mg and sitagliptin groups, respectively. Safety find-
ings are presented in Table 3. The proportion of patients 
with ≥1 adverse event was similar across the treatment 
groups. A lower percentage of patients on empagliflozin 
10 mg, empagliflozin 25 mg or sitagliptin had AEs lead-
ing to discontinuation (4.9, 4.0 and 4.9  %, respectively) 
compared with placebo (6.6 %). Two patients (0.9 %) per 
treatment group had confirmed hypoglycaemic AEs; 
one patient on empagliflozin 10 mg required assistance. 
Events consistent with UTI were reported in a similar 
proportion of patients in each treatment group (10.9, 
9.4, 9.0, and 9.0  % on placebo, empagliflozin 10  mg, 
Fig. 2 Glycaemic control a HbA1c over time [mixed model repeated measures (MMRM) in the full analysis set (FAS), observed cases (OC)]. b 
Patients with HbA1c ≥7 % at baseline who had HbA1c <7 % at week 76 (logistic regression in patients from the FAS treated in the extension trial 
using non-completers considered failures approach). c Change from baseline in FPG over time (MMRM in the FAS, OC). Empagliflozin 10 mg versus 
placebo odds ratio 4.17 (95 % CI 2.31, 7.51); empagliflozin 25 mg versus placebo odds ratio 3.96 (95 % CI 2.20, 7.14); sitagliptin versus placebo odds 
ratio 2.42 (95 % CI 1.32, 4.43). Empagliflozin 10 mg versus sitagliptin odds ratio 1.72 (95 % CI 1.04, 2.86); empagliflozin 25 mg versus sitagliptin odds 
ratio 1.64 (95 % CI 0.99, 2.72)
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empagliflozin 25  mg, and sitagliptin, respectively) and 
in a higher proportion of female than male patients. All 
events consistent with UTI were mild or moderate in 
intensity except in one patient on empagliflozin 25  mg 
and one patient on sitagliptin. Events consistent with 
genital infection were reported in a higher proportion of 
patients on empagliflozin 10 and 25 mg (5.8 and 6.3 %, 
respectively) than placebo and sitagliptin (1.7 and 0.9 %, 
respectively). All events consistent with genital infection 
were mild or moderate in intensity. Events consistent 
with volume depletion were reported in 0.4, 2.7, 0.9 and 
1.3 % of patients on placebo, empagliflozin 10 mg, empa-
gliflozin 25  mg and sitagliptin, respectively. There was 
one death in the placebo group and one death in the sit-
agliptin group (sudden death), which was not regarded 
by the investigator as related to study drug.
Small increases in haematocrit and eGFR and small 
decreases in serum uric acid were observed in the empa-
gliflozin groups (Additional file  5). Compared with pla-
cebo, there was an increase from baseline in low density 
lipoprotein (LDL) cholesterol and total cholesterol in 
patients treated with empagliflozin 25  mg and in high 
density lipoprotein (HDL) cholesterol in both empagliflo-
zin dose groups. No differences versus placebo in change 
from baseline in triglycerides or LDL/HDL cholesterol 
ratio were noted for either empagliflozin dose (Table 4).
Discussion
This extension study showed that treatment with empa-
gliflozin 10 mg or 25 mg or sitagliptin for 76 weeks led 
to sustained improvements in glycaemic control com-
pared with placebo. When compared with sitagliptin, 
empagliflozin 25 mg reduced HbA1c, and both empagli-
flozin doses reduced FPG. Furthermore, empagliflozin 
10 mg and 25 mg led to sustained weight loss compared 
with placebo or sitagliptin. The weight loss observed 
after 76  weeks’ treatment with empagliflozin is clini-
cally meaningful as weight management remains a major 
challenge in the treatment of patients with T2DM [18] 
and weight gain with glucose-lowering medication is a 
concern for the majority of patients [19, 20]. A study of 
empagliflozin 25  mg given as add-on to metformin for 
104 weeks found that nearly 90 % of the weight loss with 
empagliflozin was due to a reduction in fat mass, and that 
empagliflozin reduced both abdominal visceral adipose 
tissue and abdominal subcutaneous adipose tissue [13]. 
The initial weight loss seen with SGLT2 inhibitors may 
be due to the mild osmotic effects associated with UGE, 
but sustained weight loss is believed to result from loss of 
calories through UGE.
In previous Phase III studies, empagliflozin reduced 
SBP compared with placebo [8–12, 15, 21]. In this study, 
empagliflozin showed a reduction in SBP compared with 
placebo and sitagliptin at week 76 based on ANCOVA 
analyses with LOCF imputation, but no reductions with 
empagliflozin compared with placebo across the sensi-
tivity analyses (based on MMRM, OC). This discrepant 
result may be explained by the higher rate of early dis-
continuation and the greater need for rescue therapy in 
the placebo group.
Fig. 3 Body weight Change from baseline in body weight over time [mixed model repeated measures (MMRM) in the full analysis set (FAS), 
observed cases (OC)]
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The sustained effects of empagliflozin on glycaemic 
control and weight in this extension trial were consist-
ent with the results of a study in which patients received 
empagliflozin monotherapy for 90 weeks [22]. The effects 
of sitagliptin on glycaemic control and weight in this 
study were comparable with those observed in previous 
studies of sitagliptin monotherapy in drug-naïve patients 
with T2DM [23–25].
Recently published results of the EMPA-REG OUT-
COME® trial have shown that in patients with type 2 
diabetes and high cardiovascular risk (i.e., established 
cardiovascular disease), empagliflozin added to stand-
ard of care reduced the primary composite outcome of 
cardiovascular death, non-fatal myocardial infarction 
or non-fatal stroke (3-point major adverse cardiovas-
cular events); cardiovascular death; hospitalisation for 
heart failure; and overall mortality compared to placebo 
[21, 26]. Although the mechanisms behind the observed 
effects of empagliflozin in this patient population are not 
yet understood, they may involve reductions in hypergly-
caemia, blood pressure and weight as well as effects on 
plasma volume and sodium retention [27]; and reduc-
tions in arterial stiffness [28, 29].
Both doses of empagliflozin and sitagliptin were well 
tolerated. In accordance with its insulin-independent 
mode of action [30], and the results of previous studies, 
Table 3 Adverse events
Data from the treated set
a As reported by the investigator
b Plasma glucose ≤3.9 mmol/l and/or requiring assistance
c Based on 77 preferred terms
d Based on 89 preferred terms












Any adverse event n (%) 175 (76.4) 172 (76.8) 174 (78.0) 161 (72.2)
Drug-relateda
adverse events n (%)
36 (15.7) 49 (21.9) 52 (23.3) 31 (13.9)
Discontinuation due to adverse events n (%) 15 (6.6) 11 (4.9) 9 (4.0) 11 (4.9)
Severe adverse events n (%) 14 (6.1) 17 (7.6) 15 (6.7) 17 (7.6)
Serious adverse events n (%) 23 (10.0) 25 (11.2) 16 (7.2) 18 (8.1)
 Deaths 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.4)
Adverse events with frequency of ≥5 % in any group (by preferred term) n (%)
 Hyperglycaemia 63 (27.5) 20 (8.9) 11 (4.9) 28 (12.6)
 Nasopharyngitis 27 (11.8) 32 (14.3) 25 (11.2) 27 (12.1)
 Urinary tract infection 21 (9.2) 20 (8.9) 14 (6.3) 18 (8.1)
 Upper respiratory tract infection 12 (5.2) 17 (7.6) 16 (7.2) 19 (8.5)
 Dyslipidaemia 15 (6.6) 16 (7.1) 14 (6.3) 14 (6.3)
 Back pain 12 (5.2) 7 (3.1) 7 (3.1) 19 (8.5)
 Hypertension 13 (5.7) 11 (4.9) 5 (2.2) 14 (6.3)
 Bronchitis 10 (4.4) 11 (4.9) 6 (2.7) 12 (5.4)
 Diarrhoea 9 (3.9) 12 (5.4) 6 (2.7) 8 (3.6)
Special interest categories n (%)
 Confirmed hypoglycaemiab 2 (0.9) 2 (0.9) 2 (0.9) 2 (0.9)
  Events requiring assistance 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0)
 Events consistent with urinary tract infectionc 25 (10.9) 21 (9.4) 20 (9.0) 20 (9.0)
  Male 4 (3.2) 4 (2.8) 4 (2.8) 6 (4.3)
  Female 21 (20.0) 17 (20.7) 16 (20.3) 14 (17.1)
 Events consistent with genital infectiond 4 (1.7) 13 (5.8) 14 (6.3) 2 (0.9)
  Male 2 (1.6) 4 (2.8) 4 (2.8) 1 (0.7)
  Female 2 (1.9) 9 (11.0) 10 (12.7) 1 (1.2)
 Events consistent with volume depletione 1 (0.4) 6 (2.7) 2 (0.9) 3 (1.3)
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empagliflozin monotherapy was not associated with an 
increased risk of hypoglycaemia. In line with previous tri-
als of SGLT2 inhibitors, events consistent with genital 
infection were reported in a greater proportion of patients 
treated with empagliflozin than with placebo, and were 
more common in female than male patients [31]. Consist-
ent with previous studies of empagliflozin [9–12, 21], there 
was no higher risk of UTI in patients treated with empagli-
flozin in this study.
Strengths of the design of this study include the long 
duration, that treatment remained double-blind through-
out the extension period and the inclusion of a sitaglip-
tin group as an active comparator. Limitations of this 
study include that all endpoints, while pre-specified, were 
exploratory, with no primary endpoint defined for the 
extension study, and the amount of missing data. Only 
68 % of patients randomized in the initial 24-week study 
entered the extension period; however, this is within the 
range for extension studies of other SGLT2 inhibitors 
[32–34]. Data obtained after initiation of rescue therapy 
(5.8–32.5 % across treatment groups) were set to missing 
and imputed. Overall, 51.4 % of HbA1c data at week 76 
were imputed using a LOCF approach. The methods for 
handling missing data were analyzed by means of sensi-
tivity analyses, which revealed consistent results regard-
ing improvements in glycaemic control and weight loss 
with empagliflozin. A further limitation of this study was 
that the results may not be generalizable to all patients 
with T2DM, as for example, approximately two-thirds of 
the patients in the trial were Asian.
In conclusion, results from this extension study indi-
cate that empagliflozin 10 mg and 25 mg given as mon-
otherapy to drug-naïve patients with T2DM leads to 
sustained improvements in glycaemic control and reduc-
tions in weight compared with placebo and sustained 
reductions in HbA1c (for empagliflozin 25  mg), weight 
and SBP compared with sitagliptin over 76 weeks.
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